医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

SanBio’s US-based Phase 1/2a Clinical Trial of SB623 for the Treatment of Chronic Motor Deficit from Ischemic Stroke Was Addressed at an Event Held by California Institute for Regenerative Medicine (CIRM)

2018年06月15日 AM11:30
このエントリーをはてなブックマークに追加


 

TOKYO

The SanBio Group (SanBio Co., Ltd. and subsidiary SanBio, Inc.), a scientific leader in regenerative medicine for neurological disorders, hereby announces that the US-based phase 1/2a clinical trial of SB623 for the treatment of chronic motor deficit from ischemic stroke conducted by the SanBio group was addressed at an event held by California Institute for Regenerative Medicine (CIRM) on May 31, 2018.

The recording of the event is available for view at https://www.facebook.com/CaliforniaInstituteForRegenerativeMedicine/

SanBio, Inc. and SanBio Co., Ltd.

SanBio group is engaged in the regenerative medicine business spanning research, development, manufacture, and sales of regenerative medicines. In regards to its propriety regenerative medicine product SB623, SanBio is conducting a phase 2b clinical trial for the treatment of chronic motor deficit from ischemic stroke in the US together with its development partner in the US and Canada, Sumitomo Dainippon Pharma Co., Ltd. On its own, SanBio is conducting a global phase 2 clinical trial of SB623 targeting chronic motor deficit from TBI in Japan and the US. Headquartered in Tokyo, SanBio has its main R&D base in Mountain View, California in the US.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180614006372/en/

CONTACT

For more information, contact:
SanBio Co., Ltd.
Masahito
Kumagae, +81-3-6264-3481
Management Administration

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Seoul Viosys’ Violeds Modules Proven to Disinfect 99% of Airborne Viruses in a Recent Testing Result
  • Kaye® (ケイ)は、COVID-19ワクチンの輸送・保管のニーズに応えるためにKaye® ログ -80ワクチン温度ロガーを、コールドチェーン市場向けに導入(発売)します。
  • Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
  • Kaye推出适用于冷链运输市场的Kaye® Log -80℃ 疫苗温度记录器,以满足COVID-19疫苗储存和运输的要求
  • DNP的新型非接触式透明屏幕可通过手的动作进行操作